SkinTE by RegenETP for Diabetic Foot Ulcers: Likelihood of Approval

SkinTE is under clinical development by RegenETP and currently in Phase III for Diabetic Foot Ulcers.

Analysts highlight Masimo’s advantages over Apple, Fitbit ahead of proxy vote

Dive Brief: Analysts at Stifel have given a boost to Masimo ahead of a key shareholder vote, highlighting the potential for its W1 watch to

June 20, 2023

Some early-stage, low-risk breast cancer patients may not need radiotherapy after surgery

Some women with early-stage, low-risk breast cancer may not need radiotherapy after breast conserving surgery according to new research led by McMaster University, BC Cancer,

August 17, 2023

Dewpoint and Chemify partner for cancer drug discovery

Chemify will carry out the design and delivery of new compounds to boost the oncology and neurodegeneration pipeline of Dewpoint. Credit: metamorworks/Shutterstock.com. Dewpoint Therapeutics has

September 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.